Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Brookfield Infrastructure Partners LP — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Brookfield Infrastructure Partners LP trades at $36.86 (market cap $16.97B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 3.8× ACADIA Pharmaceuticals Inc.'s market cap, and Brookfield Infrastructure Partners LP pays a 4.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BIP | |
|---|---|---|
Market Cap | $4.49B | $16.97B |
Sector | Health | Industrials |
52-Week High | $28.06 | $40.08 |
52-Week Low | $20.06 | $29.81 |
Enterprise Value | $3.69B | $78.64B |
Dividend Yield | — | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Brookfield Infrastructure Partners (BIP) trades at $37.31, up 0.81% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock carries a high P/E of 56.53 but attractive P/S of 0.71 and EV/EBITDA of 7.53. Recent earnings show volatility with two misses in the last three quarters, though Q2 2026 results are pending. The company maintains strong cash flow from operations of $6.0 billion and recently declared a $0.46 dividend.
BIP offers value through its discounted valuation and 5% yield, supported by inflation-linked contracts and infrastructure assets. However, risks include recent earnings misses, high debt levels, and sensitivity to interest rates. Analyst consensus is strongly bullish with a $45.50 price target, suggesting 22% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
